
Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target
IL-27 pathway blockade is gaining traction in early-phase clinical trials as a mechanism for reducing IL-27–mediated antitumor immune system suppression in solid tumors, most notably hepatocellular carcinoma (HCC) and non–small cell lung cancer (NSCLC), in …